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Carolyn M. Ricketts, BSN, RN-C
Otterbein University, Westerville, Ohio
Introduction
Neurologic diseases are often difficult to
comprehend since the Neurosystem is
very complex. Multiple Sclerosis (MS) is
among one of the many neurologic
diseases in which there is no cure and it
is unknown why exactly it develops.
According to Khorramdelazad, H.,
Bagheri, V., Hassanshahi, G., Zeinali, M., &
Vakilian, A. (2016), MS “is the main cause
of nontraumatic neurological disability in
young adults” (p. 72). MS is a chronic
autoimmune inflammatory disease
resulting from inflammation of the
central nervous system (CNS), bloodbrain-barrier (BBB) breakdown, and
demyelination of the brain and spinal
cord white matter leading to lesions and
axonal damage affecting the CNS (Guan,
Y., Jakimovski, D., Ramanathan, M.,
Weinstock-Guttman, B., & Zivadinov, R.,
2019). This damage is followed by
complete or partial recovery with scaring
or sclerosis (McCance, K. L., & Huether, S.
E. (eds.)., 2018). Family Nurse
Practitioners (FNP) and other healthcare
professionals need to understand and
assist with early treatment as well as
manage lifelong treatment for the MS
patient to maintain or improve quality of
life.

Risk Factors
•
•

•
•

•

Greatest risk: Infectious
mononucleosis during early adulthood
Exposure to the Epson-Barr virus
(EBV) (present in 90% of the general
population, 30-40% of those will
develop infectious mononucleosis)
Reactivation of EBV has a positive
correlation with relapses
Smoking ⟶ Worse disease
progression & worse MRI outcomes
Vitamin D deficiency ⟶ hypothesized
to increase risk of developing MS,
causing worse outcomes & higher
occurrence of relapses
MS occurs in higher rates in areas
further from the equator
(Guan et al, 2019).

Signs & Symptoms
• Onset between 20-40 years; life
expectancy not greatly altered
• More common in females
• Males may have more severe
progressive course
• First demyelinating event: commonly a
single neurologic dysfunction lasting
longer than 24 hours without fever,
infection, or encephalopathy.
• Multifocal: Paresthesia of the face,
trunk, or limbs, weakness, impaired
gait, visual disturbances, urinary
incontinence, optic neuritis most
commonly in one eye with progressive
blurring & pain
• Spinal cord syndrome: in sensory or
motor tracks starting on one side of the
body & progressing to the other,
• Brainstem syndromes: facial sensory
loss or weakness, vertigo, or double
vision.
• Cerebellar syndromes: lack of
coordination, tremor, gait instability,
ataxia.
• Cerebrum symptoms: hemifacial
weakness, pain, motor impairments.
• Cognitive impairments: occur later in
disease: memory & attention problems
as well as Psychiatric disorders,
depression, dementia
(McCance, K. L., & Huether, S. E. (eds.).,
2018).
• Characterized by flare-ups or attacks of
symptoms that can last from days to
weeks. Can either resolve or become
permanent (Khorramdelazad et al,
2016).
• 70% of MS patients experience
cognitive impairment from mild
forgetfulness to mild to moderate
dementia (Maloni, H., 2018)

Underlying
Pathophysiology
• “A diffuse and progressive CNS
inflammatory autoimmune disease that
affects white and gray matter”
anywhere in the CNS (McCance, K. L., &
Huether, S. E. (eds.)., 2018, p. 581).
• Adaptive & innate immunity involved
⟶ inflammation from oxidative injury
& mitochondrial dysfunction from
oxidative free radicals in microglia &
macrophages. Oxidative injury
amplified with aging by microglia
activation, progressive mitochondrial
damage, & accumulation of iron in the
CNS (Grigoriadisa, N., & Van Pesch, V.,
2015).
• B cells, T cells, & macrophages breech
BBB of the brain & spinal cord,
“recognize myelin autoantigens and
produce myelin-specific antibodies
triggering inflammatory
demyelination” (McCance, K. L., &
Huether, S. E. (eds.)., 2018, p. 581).
• Leads to loss of oligodendrocytes &
myelin sheaths ⟶ disrupt nerve
connections (McCance, K. L., & Huether,
S. E. (eds.)., 2018).
• TH1 & TH17 pro-inflammatory
lymphocytes activated in periphery,
cross the BBB, penetrate the CNS & are
reactivated by CNS antigens inducing
an inflammatory response inducing
macrophage & microglial activation
creating more pro-inflammatory
mediators, oxygen, & nitric oxide
radicals causing demyelination &
axonal loss (Grigoriadisa, N., & Van
Pesch, V., 2015).
• Relative preservation of axons & glial
or astrocytic scar formation
• Relapse = at least partial repair
• Progressive forms can lead to death of
neurons and brain atrophy
(McCance, K. L., & Huether, S. E. (eds.).,
2018

Multiple Sclerosis Case
A 24-year-old Caucasian female visits a Columbus, Ohio clinic with complaints of blurry
vision in her right eye that started two days ago. She states she is tired all the time and has
been having “weird things” occurring to her for the past several years, such as the inability
to concentrate, trouble following simple instructions at times, sharp pains shooting through
her right arm at random, and being unstable on her feet occasionally. Her symptoms have
always resolved and she states she “always contributed it to stress.”
She has a history of infectious mononucleosis as a teenager.
Physical examination reveals right-hand grasp is slightly weaker than left, nystagmus of the
right eye, and some pain with eye movement.
She is afebrile, vital signs are normal, no findings of any infection
She is referred to a neurologist and a brain MRI is ordered, which reveals a diagnosis of MS
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RelapsingRemitting
Most common
Primary
Progressive
Least Common

•

•
•

The gut microbiome & dietary patterns
Genetic susceptibility
(Grigoriadisa, N., & Van Pesch, V., 2015)

•
•

•

The Hygiene Hypothesis: Areas with
better hygiene & sanitation result in
youth exposed to less pathogens
leading to higher rates of autoimmune
diseases (Guan et al, 2019).

•
•

Epson-Barr Virus and the Two-Hit Hypothesis Pathophysiology of MS:
Memory B cells (antigen presenting cells) act as reservoirs for EBV & are
thought to enhance BBB permeability allowing pre-existing polyclonal antibodyproducing B cells to enter the CNS
Memory B cells activate auto-aggressive T-cells against myelin proteins
High levels of CD40 on B cells suggest a higher level of antigen presentation of
EBV; associated with higher levels of neurodegeneration & found in actively
demyelinating lesions
EBV immortalizes Memory B cells interacting with tumor suppressor genes ⟶
become undetectable to T-cell surveillance
(Guan et al, 2019).
Acute axonal damage has been correlated with CD8+ T cells, pro-inflammatory
mediators with cytologic activity against EBV, found in the brain & cerebral
spinal fluid (Grigoriadisa, N., & Van Pesch, V., 2015)

Secondary
Progressive

Progressive
Relapsing

Symptoms

Recurring exacerbations of
previous symptoms with acute
axonal loss followed by complete
or partial recovery that lasts
days to months (Guan et al,
2019).
Gradual progression &
continuously accumulating
physical disability without
relapse (Guan et al, 2019).

Area of Impact

Dominated by multifocal
inflammatory demyelinated
plaques in white matter
(Grigoriadisa, N., & Van Pesch,
V., 2015).
Most prevalent in the spinal
cord with gradual loss of power
in lower limbs, asymmetric,
bowel & bladder problems
(McCance, K. L., & Huether, S. E.
(eds.)., 2018).
Inflammation
compartmentalized in the CNS
“characterized by the presence
of ectopic lymphoid follicles
particularly in the meninges”
(Grigoriadisa, N., & Van Pesch,
V., 2015, p.8).

Relapsing-remitting evolve
into progressive disease
with worsening disability
with or without relapses
(Guan et al, 2019
•
Relapses get shorter in
duration & symptoms
progressively more severe
(McCance, K. L., & Huether,
S. E. (eds.)., 2018).
“Steadily worsening symptoms from the onset with clear acute
relapses but often with more severe symptoms” (McCance, K. L., &
Huether, S. E. (eds.)., 2018, p. 582).
•

Human CXCL12 gene and cytokine:
• may be responsible for causing
inflammation, remyelination, &
neuroprotection
• Facilitate leukocyte recruitment &
migration into the CNS
• Important for developmental
processes such as hematopoiesis,
cardiogenesis, vascular formation,
neurogenesis
• Alterations in CXCL12 gene
expression, located on chromosome
10, recruits & facilitates CXCR4expressing mononuclear cells
across BBB leading to progression
& development of MS
• Active and silent lesions have
CXCL12 present
(Khorramdelazad et al, 2016).
• Axonal transection & damage:
Linked to brain atrophy in MS at a
rate of 0.5-1% per year correlates
with physical & cognitive disability
(Grigoriadisa, N., & Van Pesch, V.,
2015)

Significance of
Pathophysiology

MRI is the most sensitive tool to diagnose & monitor
MS (Guan et al, 2019). These photos are MRIs of
patients with MS. Macrophages & microglial cells
have been found in active MS lesions” (McCance, K.
L., & Huether, S. E. (eds.)., 2018).
Symptom subtype
of MS

Pathophysiology
Continued

Early diagnosis & initiation of treatment
is important!
• Get inflammation under control to
decrease the amount of damage,
preventing permanent disability
• Discovering the exact pathology of MS
will assist in new treatments & maybe
someday a cure
• Main therapies are focusing on antigen
presentation, peripheral immune
response, the BBB, & target tissue in
the CNS
(Grigoriadisa, N., & Van Pesch, V.,
2015)
• CXCR4 & CXCL12 currently being
researched as a therapeutic target for
several systematic autoimmune &
neuroinflammatory diseases, such as
MS. Serum levels of CXCL12 have
potential to be used as a MS prognosis
biomarker. Increased levels may
correlate with increased levels of
autoimmunity
(Khorramdelazad et al, 2016)
• Research for EBV vaccination, not
successful currently (Guan et al,
2019).

Nursing Implications
Family nurse practitioners (FNP) in northern United States may encounter MS often
(Guan et al, 2019).
MS patients need a well-coordinated team of professionals with shared decision
making to diagnose and treat symptoms of MS successfully and improve or
maintain quality of life.
FNP role is important in assisting with diagnosis & life-time management:
• Screen for & manage symptoms
• Ask the right questions to discover compensatory behavior & strategize with the
patient on ways to improve quality of life:
• Everyday life ?s: problems with driving, cooking, following a recipe,
participating in a group activity.
• Look at underlying conditions that could be causing cognitive impairment
• The Symbol Digit Modalities Test = quick, cost-effective screening for cognitive
impairment
• Symptom treatment, interpret lab results, communicate diagnosis, referrals for
cognitive rehabilitation & neurologists
• Assist with disability at work & home: cool environment, ergonomic seating,
handicap parking, compensatory techniques: recording, planning, use of smart
phone apps & reminders, removing distractions, rest, & restorative therapies
• Counsel & advocate for patients & families
• Educate on wellness behaviors: diet high in fruits & vegetables & low in meats,
taking antioxidants, vitamin D importance, lifestyle factors, & exercise
(Maloni, H., 2018).
• Educate MS patients on disease modifying therapies (DMT); several available
making options complex.
• FNPs teach & be sure patients understand short & long-term side effects, treatment
guidelines, & treatment monitoring to maximize success.
• Set realistic expectations, MS is not curable, treatments intended to slow disease
progression & limit disease activity.
• FNPs monitor & manage side effects of DMTs
(Roman, C., & Menning, K, 2017)

Conclusion
Multiple sclerosis is a debilitating
autoimmune disease characterized by
inflammation, demyelination, and
damage to nerves with or without
relapse. The exact pathology is
unknown, but many theories include
cells of the innate and adaptive immune
system crossing over the BBB and
initiating damaging inflammation.
Infection by EBV and alteration of the
CXCL12 gene are two theories in the
pathophysiology and development of MS.
The pathophysiology is important for the
development of new treatments, possible
vaccination, and a possible cure
someday. The FNP has an important role
of screening patients, making referrals to
correct medical providers, educating and
advocating for the patient, and
monitoring and managing symptoms
throughout the MS patients life.
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